Belgium· BE-AMP-SAM578577-00
Phesgo 1200 mg - 600 mg
A pertuzumab und trastuzumab product containing pertuzumab, registered in Belgium by Roche Registration. The same ATC class is registered in 10 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Pertuzumab und trastuzumab is registered in 10 of 19 countries.
Countries holding a registration under ATC L01FY01 (pertuzumab und trastuzumab), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 7 of them publish a price we can compare per daily dose
Pertuzumab und trastuzumab · ATC L01FY01
10 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Pertuzumab
- Manufacturer
- Roche Registration
- Country
- Belgium (BE)
- ATC code
- L01FY01
- ATC class
- Pertuzumab und Trastuzumab
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 1
- be_apb4284204
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Pertuzumab und trastuzumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainPERJETA 420 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONRoche Registration Gmbh
- FinlandPerjeta2care4 ApS
- CzechiaPERJETARoche Registration GmbH, Grenzach-Wyhlen
- United KingdomPerjeta 420mg/14ml concentrate for solution for infusion vialsOriginalis B.V.
- IrelandPerjeta 420 mg concentrate for solution for infusionRoche Registration GmbH
- IcelandPerjetaRoche Registration GmbH*
- NetherlandsPerjeta, 420 mg Concentraat voor oplossing voor infusieRoche Registration GmbH
- PolandPerjetaRoche Registration GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Perjeta, Poherdy
- Liechtenstein · Perjeta, Poherdy
- Norway · Perjeta, Poherdy
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cd918ce8-058e-4556-87d8-fc9b9aab6cf5 GET /v1/drugs/cd918ce8-058e-4556-87d8-fc9b9aab6cf5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Phesgo 1200 mg - 600 mg",
"name_fr": "Phesgo 1200 mg - 600 mg",
"name_nl": "Phesgo 1200 mg - 600 mg",
"amp_code": "SAM578577-00",
"strengths": [
"80.0000",
"40.0000"
],
"pack_count": 1,
"substances": [
"Pertuzumab",
"Trastuzumab",
"Sucrose",
"Polysorbate 20"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Pertuzumab and Trastuzumab",
"authorisation_numbers": [
"EU/1/20/1497/001"
]
}See everything about pertuzumab und trastuzumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.